JP2018514564A - 肺送達用のゾルミトリプタン粉末 - Google Patents

肺送達用のゾルミトリプタン粉末 Download PDF

Info

Publication number
JP2018514564A
JP2018514564A JP2017556853A JP2017556853A JP2018514564A JP 2018514564 A JP2018514564 A JP 2018514564A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2018514564 A JP2018514564 A JP 2018514564A
Authority
JP
Japan
Prior art keywords
powder
zolmitriptan
powder formulation
particles
leucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017556853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018514564A5 (enExample
Inventor
リップ,マイケル,エム.
Original Assignee
サイヴィタス セラピューティックス,インコーポレイテッド
サイヴィタス セラピューティックス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイヴィタス セラピューティックス,インコーポレイテッド, サイヴィタス セラピューティックス,インコーポレイテッド filed Critical サイヴィタス セラピューティックス,インコーポレイテッド
Publication of JP2018514564A publication Critical patent/JP2018514564A/ja
Publication of JP2018514564A5 publication Critical patent/JP2018514564A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017556853A 2015-05-01 2016-04-29 肺送達用のゾルミトリプタン粉末 Pending JP2018514564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562155910P 2015-05-01 2015-05-01
US62/155,910 2015-05-01
PCT/US2016/030219 WO2016179026A1 (en) 2015-05-01 2016-04-29 Zolmitriptan powders for pulmonary delivery

Publications (2)

Publication Number Publication Date
JP2018514564A true JP2018514564A (ja) 2018-06-07
JP2018514564A5 JP2018514564A5 (enExample) 2019-06-06

Family

ID=56027187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017556853A Pending JP2018514564A (ja) 2015-05-01 2016-04-29 肺送達用のゾルミトリプタン粉末

Country Status (9)

Country Link
US (1) US20160317503A1 (enExample)
EP (1) EP3288591A1 (enExample)
JP (1) JP2018514564A (enExample)
KR (1) KR20180002750A (enExample)
AU (1) AU2016257729A1 (enExample)
CA (1) CA2984339A1 (enExample)
HK (1) HK1251998A1 (enExample)
MX (1) MX2017013950A (enExample)
WO (1) WO2016179026A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021535191A (ja) * 2018-11-13 2021-12-16 シヴィタス セラピューティクス、インコーポレイテッド 吸入用の呼吸可能なポリヌクレオチド粉末製剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1254670A1 (zh) * 2015-07-02 2019-07-26 Civitas Therapeutics, Inc. 曲普坦粉末用於肺部给药
JP7419253B2 (ja) * 2017-12-21 2024-01-22 キウィタス セラピューティクス,インコーポレイテッド 吸入のための界面活性剤製剤
MX2022014216A (es) 2020-05-18 2022-12-07 Orexo Ab Nueva composicion farmaceutica para administracion de farmacos.
IL313016A (en) 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520843A (ja) * 2002-03-20 2005-07-14 アドバンスト インハレーション リサーチ,インコーポレイテッド 呼吸用持続性治療製剤
JP2011510964A (ja) * 2008-02-01 2011-04-07 ヴェクトゥラ リミテッド トリプタン類の肺用製剤
JP2013545748A (ja) * 2010-11-09 2013-12-26 マンカインド コーポレイション セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US8496002B2 (en) 2007-06-12 2013-07-30 Civitas Therapeutics, Inc. Powder inhaler devices
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005520843A (ja) * 2002-03-20 2005-07-14 アドバンスト インハレーション リサーチ,インコーポレイテッド 呼吸用持続性治療製剤
JP2011510964A (ja) * 2008-02-01 2011-04-07 ヴェクトゥラ リミテッド トリプタン類の肺用製剤
JP2013545748A (ja) * 2010-11-09 2013-12-26 マンカインド コーポレイション セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021535191A (ja) * 2018-11-13 2021-12-16 シヴィタス セラピューティクス、インコーポレイテッド 吸入用の呼吸可能なポリヌクレオチド粉末製剤
JP7632959B2 (ja) 2018-11-13 2025-02-19 メルツ ファーマスーティカルズ, エルエルシー 吸入用の呼吸可能なポリヌクレオチド粉末製剤

Also Published As

Publication number Publication date
MX2017013950A (es) 2018-08-28
CA2984339A1 (en) 2016-11-10
WO2016179026A1 (en) 2016-11-10
AU2016257729A1 (en) 2017-11-09
KR20180002750A (ko) 2018-01-08
US20160317503A1 (en) 2016-11-03
HK1251998A1 (zh) 2019-05-10
EP3288591A1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
RU2670987C2 (ru) Порошки для ингаляции с ультранизкой плотностью
US9155699B2 (en) Pulmonary delivery for levodopa
JP2018514564A (ja) 肺送達用のゾルミトリプタン粉末
JP2018535984A (ja) リバビリンの医薬組成物
ES3022184T3 (en) Rapamycin powders for pulmonary delivery
CN116687887A (zh) 用于吸入的干粉制剂
WO2011139253A2 (en) Pharmaceutical compositions comprising ceftibuten
CN102920678A (zh) 一种奥氮平固体制剂及其制备方法
US20240033218A1 (en) Dihydroergotamine dry powder formulations and methods of use
US10034857B2 (en) Triptan powders for pulmonary delivery
WO2025157904A1 (en) Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
US20060222599A1 (en) Inhalative powder formulations containing the CGRP-antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
CA2536050A1 (en) Novel inhalation powder comprising the cgrp antagonist 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine
HK40023697A (en) Ultra low density pulmonary powders
WO2011139250A2 (en) Water dispersible formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803